| Identification | Back Directory | [Name]
1H-Pyrazole-3-carboxamide, N-[5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1-propyl-4-(2,2,2-trifluoroethoxy)- | [CAS]
2394874-66-7 | [Synonyms]
1H-Pyrazole-3-carboxamide, N-[5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1-propyl-4-(2,2,2-trifluoroethoxy)- | [Molecular Formula]
C25H24F3N5O5 | [MOL File]
2394874-66-7.mol | [Molecular Weight]
531.48 |
| Chemical Properties | Back Directory | [Boiling point ]
600.6±55.0 °C(Predicted) | [density ]
1.38±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
10.56±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
Adrixetinib is a tyrosine kinase inhibitor with potential use as an antineoplastic agent. | [Uses]
Adrixetinib (Q702) is an Axl/Mer/CSF1R protein tyrosine kinase inhibitor with antineoplastic activity[1][2]. | [References]
[1] WHO Drug Informat ion - World Health Organization (WHO). [2] Nam Kiyean, et al. Quinoline derivatives as inhibitors of Axl/Mer RTK and CSF1R and their preparation: World Intellectual Property Organization, WO2019229251. 2019-12-05. [3] WHO Drug Information-World Health Organization (WHO). |
|
|